Distinct Healthcare · Weight Management

Ozempic & Wegovy: A Plain-Language Guide
to Weight Management Support

Late-night cravings, weight that keeps coming back, high blood sugar making it even harder — this guide explains what these two medications actually do, who they are right for, and how to use them alongside genuine lifestyle changes for results that last.

Eligibility by BMI & comorbidities Dose escalation schedule Side effect management guide
I
Am I a Candidate for These Medications?
The two core assessment criteria are BMI (Body Mass Index) and the presence of weight-related comorbidities. Your physician will make the final determination based on your complete clinical picture.
How to calculate your BMI
Weight (kg) ÷ Height (m) ÷ Height (m)
Example: 70 kg, 1.70 m tall → BMI = 70 ÷ 1.70 ÷ 1.70 ≈ 24.2
Reference ranges: BMI < 18.5 = underweight; 18.5–22.9 = normal; 23–27.4 = overweight; ≥ 27.5 = obese (Asian-adapted criteria used in Singapore). Some clinical guidelines use BMI ≥ 27 / ≥ 30 as the overweight / obese thresholds — your physician will apply the locally appropriate standard.
The appropriate BMI thresholds for prescribing these medications in Singapore are determined by Health Sciences Authority (HSA) approval and your physician's clinical judgement.
Ozempic
Semaglutide injection · Maximum 1 mg weekly
Type 2 diabetes Regardless of weight — indicated for blood glucose management and cardiovascular risk reduction (heart attack, stroke), with secondary weight loss benefits. Core indication
No diabetes Requires: BMI ≥ 30 (obesity alone), or BMI ≥ 27 plus at least one comorbidity (hyperglycaemia, hypertension, or obstructive sleep apnoea). Constitutes off-label use — informed consent required after physician evaluation. Note: Ozempic does not hold an FDA or HSA approval for weight loss. The approved semaglutide formulation for weight management is Wegovy — where weight loss is the primary goal, Wegovy should be the first-line option.
Max dose 1 mg per week (maintenance dose determined by physician)
Wegovy
Semaglutide injection · Maximum 2.4 mg weekly
Core purpose Specifically designed for long-term weight management. Clinical trials: the STEP 1 trial demonstrated average weight reduction of 14.9% over 68 weeks (placebo: 2.4%); the STEP 3 trial, combined with intensive lifestyle intervention, reached 16.0% (individual results vary significantly).
Indicated for BMI ≥ 30 (obesity), or BMI ≥ 27 with at least one comorbidity: hyperglycaemia, hypertension, dyslipidaemia, or cardiovascular disease. Core indication
Max dose 2.4 mg per week (maintenance dose determined by physician)
Absolute contraindications — disclose these to your doctor before any prescription: Personal or family history of medullary thyroid carcinoma (MTC), or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN 2). Rodent studies suggest semaglutide may increase the risk of thyroid C-cell tumours; to date, large-scale human clinical studies have not confirmed an increased risk of thyroid cancer with semaglutide, but high-risk individuals must still be strictly excluded. Your physician will ask about family history during the initial consultation — answer fully and accurately.
BMI below 27? Neither medication is appropriate. Your physician will recommend dietary guidance, physical activity, and behavioural support — approaches that are equally effective and better suited to your current situation.
II
What Problems Do These Medications Actually Solve?
GLP-1 receptor agonists don't "burn fat" directly. They work by addressing the physiological mechanisms that make sustained weight loss so difficult for many people.

Hunger without the battle

Acts on appetite-regulating centres in the brain to reduce hunger signals, while simultaneously slowing gastric emptying to extend post-meal satiety. Where hunger used to return within two hours, it may now take four — eating less feels natural, not forced.

Stable blood glucose, fewer cravings

Ozempic stimulates insulin secretion and suppresses glucagon, helping people with type 2 diabetes maintain stable blood glucose. Stable glucose levels reduce the sudden carbohydrate cravings triggered by hypoglycaemia — keeping dietary plans on track.

Relieving the downstream effects

As weight falls, blood pressure, lipid levels, sleep apnoea, and joint strain typically improve in parallel — these are benefits of weight reduction itself, not direct drug effects. The SUSTAIN-6 trial (Ozempic) and the SELECT trial (Wegovy) both demonstrated a reduction in major adverse cardiovascular events (MACE) of approximately 14–20% in high-risk patients. In 2024, the FDA approved Wegovy for secondary prevention of cardiovascular events in adults with established cardiovascular disease. Weight reduction also independently improves blood pressure, lipid profiles, and reduces joint and respiratory burden.

These medications are adjunctive tools, not complete solutions. Research consistently shows that medication combined with dietary change and regular physical activity produces significantly better and more durable weight loss than medication alone.
III
Side Effects: What's Normal and What Needs Attention
The vast majority of side effects are mild, temporary, and well-managed with simple adjustments. A small number of serious reactions require immediate medical attention.

Common reactions — typically resolve within 1–2 weeks as the body adjusts

What you may experience

  • Nausea (~33–44% of patients) and vomiting (~11–25%) — most common, especially during initiation and dose escalation; typically mild to moderate and transient
  • Diarrhoea (~23–31%), constipation, bloating
  • Mild headache and fatigue

Practical management tips

  • Switch to five small meals throughout the day rather than three large ones
  • Plain crackers or cold, lightly seasoned congee can help settle nausea
  • Avoid high-fat and high-sugar foods — greasy or very sweet food significantly worsens nausea

Stop the medication and seek immediate medical attention if any of these occur

  • Persistent severe abdominal pain: May indicate acute pancreatitis. Do not wait — go to A&E or call 995 immediately.
  • Difficulty breathing, facial or throat swelling, widespread rash: Signs of a severe allergic reaction. Call 995 immediately.
  • Dizziness, palpitations, cold sweating, or confusion: Symptoms of hypoglycaemia — particularly if used alongside insulin or sulphonylurea agents. Take sugar immediately and seek medical attention.
  • Blurred or double vision: Requires urgent ophthalmological assessment to rule out progression of diabetic retinopathy.
IV
Dosing: Starting Low and Building Up Gradually
Both medications follow the same principle — begin at the lowest dose and increase incrementally, giving the body time to adjust and minimising gastrointestinal side effects along the way

Wegovy standard escalation schedule

Period
Weekly dose
Weeks 1–4
0.25 mg (initiation)
Weeks 5–8
0.5 mg
Weeks 9–12
1.0 mg
Weeks 13–16
1.7 mg
Week 17+
1.7 mg or 2.4 mg (maintenance; physician-determined)

Four things you must know about usage

  • Never self-adjust the dose. Escalation speed is based on your tolerability — moving too fast significantly increases the risk of adverse reactions.
  • Ozempic and Wegovy are not interchangeable. Ozempic's maximum maintenance dose is 1 mg; Wegovy's is 2.4 mg. Despite the same active ingredient, switching without physician evaluation is unsafe.
  • Missed dose: Both Ozempic and Wegovy follow the same rule — if fewer than 5 days have elapsed since the missed dose, administer it as soon as possible and resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose entirely and resume on the next scheduled day. Never double up to compensate.
  • Storage: Unopened: refrigerate at 2–8°C, away from light; never freeze. After opening: store at room temperature (≤ 30°C) or refrigerated; use within 28 days (per FDA labelling for Wegovy; follow the local package insert for the precise timeframe).
Injection sites: Subcutaneous injection into the abdomen (at least 5 cm from the navel), outer upper arm, or outer thigh. Rotate sites with each injection to prevent localised hardening. All needles are single-use only — remove and dispose of immediately after each injection.
V
Medication Alone Is Not Enough: Building Habits That Stick
The medication gets you through the hardest part. The habits you build are what keep the weight off — small, sustainable changes beat extreme plans every time.

Diet: small swaps, not extremes

  • Replace one sugary drink a day with unsweetened tea or water — a change that easily saves 200 calories daily
  • Plate structure: half vegetables, one quarter protein, one quarter carbohydrates — filling without excess
  • When hungry between meals, reach for cherry tomatoes, cucumber, or a small handful of unsalted nuts instead of crisps or biscuits

Exercise: start where you are

  • A 20-minute walk after dinner is a proven starting point — alighting one stop early is an easy way to build this habit
  • Three sessions per week of 30 minutes at moderate intensity — swimming, cycling, or brisk walking; aim to raise your heart rate slightly
  • Break up long periods of sitting — even standing or walking briefly during work breaks adds up meaningfully over time

Pace: slow and steady wins

  • 0.5–1 kg per week is a sustainable, medically sound rate — rapid weight loss is mostly fluid and highly prone to rebound. Important note on stopping: The STEP 4 trial showed that, on average, patients regained approximately 6.9% of body weight after discontinuing Wegovy. This underscores that these medications typically require long-term use, and any decision to stop should be made in consultation with your physician
  • Physicians typically set staged targets — for example, reducing body weight by 5% first — before progressing further
  • Once habits are well-established, your doctor will reassess whether medication can be gradually tapered
VI
Three Things to Keep in Mind
Weight management is not something these medications do for you. It's something they help you do — and that distinction matters enormously for long-term outcomes.

Before You Begin

  • 1
    Prescription only — obtain through a licensed medical institution. Both Ozempic and Wegovy require a physician's prescription in Singapore. Never purchase through unverified online channels — the risk of counterfeit or substandard products is real and serious. Your doctor will tailor the dosing schedule to your weight, health profile, and concurrent medications.
  • 2
    These are adjunctive tools, not a shortcut. Continuing poor dietary habits, insufficient sleep, and physical inactivity while on medication will significantly limit results. The medication helps you break through the plateau — the habits you develop during treatment are what sustain the outcome once the medication is eventually tapered.
  • 3
    When in doubt or in discomfort, contact your doctor — not a search engine. If you experience unexpected symptoms, tell your doctor promptly rather than waiting it out. For specific dietary advice, ask your doctor or a registered dietitian for a personalised plan rather than relying on generic online guidance.
References
References are numbered sequentially (1–23) in the order they appear by thematic category. All citations follow Vancouver style. This article was reviewed against evidence available as of the publication date.
Indications, Approvals & Overview
  • 1.Dhillon S. Semaglutide: first global approval. Drugs. 2018;78(2):275–284.
  • 2.U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. FDA; 2026.
  • 3.U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information. FDA; 2025.
  • 4.U.S. Food and Drug Administration. Oral semaglutide label — boxed warning. FDA; 2026.
  • 5.Scannell C, Ganguli I, Zhang C, et al. Prescription fills for semaglutide products by payment method. JAMA Health Forum. 2024;5(2):e235017.
  • 6.Nadolsky K, Almandoz JP, Apovian CM, et al. American Association of Clinical Endocrinology consensus statement on obesity treatment — 2025 update. Endocr Pract. 2025;31(4):426–456.
  • 7.Mares AC, Rao S, Lastra G, et al. Semaglutide for weight loss and cardiometabolic risk reduction in overweight and obesity. Curr Opin Cardiol. 2022;37(5):484–495.
Weight Reduction Efficacy
  • 8.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
  • 9.Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403–1413.
  • 10.Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705–719.
  • 11.Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000–2015.
  • 12.Bracchiglione J, Boltzer M, Camacho M, et al. Semaglutide for adults living with overweight or obesity: a Cochrane systematic review. Cochrane Database Syst Rev. 2025.
  • 13.Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198–1225.
Cardiovascular Benefits
  • 14.Sadraei S, Alemi H, Mirhashemi M, et al. Cardiovascular benefits of semaglutide and other GLP-1 receptor agonists: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2025;25:29.
  • 15.McGuire DK, Busui RP, Deanfield J, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SOUL trial). N Engl J Med. 2025 [Epub ahead of print].
  • 16.Marx N, Sattar N, Jering K, et al. Oral semaglutide and cardiovascular outcomes according to baseline SGLT2 inhibitor use. Circulation. 2025;151(15):1095–1106.
  • 17.Westerink J, Bhatt DL, Steg PG, et al. Life-years gained free of cardiovascular events with semaglutide: a post-hoc analysis. Diabetes Care. 2022;45(2):386–394.
Side Effects & Safety
  • 18.Kushner RF, Batsis JA, Bradley D, et al. Managing adverse effects of incretin-based medications. JAMA. 2025;333(4):333–341.
  • 19.Bald E, Raber H. Semaglutide (Wegovy) for treatment of obesity. Am Fam Physician. 2023;108(2):185–186.
  • 20.Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245–2257.
  • 21.Apovian CM, Aronne LJ, Bessesen DH, et al. Clinical management of obesity — third edition. The Obesity Society; 2025.
Thyroid Cancer Risk
  • 22.Vilsbøll T, Bain SC, Leiter LA, et al. Thyroid cancer risk associated with GLP-1 receptor agonist use: a real-world pharmacovigilance analysis. Diabetes Obes Metab. 2025;27(3):1122–1131.
  • 23.Kelly CA, Sipos JA. Approach to the patient with thyroid nodules in the context of GLP-1 receptor agonist use. J Clin Endocrinol Metab. 2025;110(4):e1245–e1254.
Disclaimer & Credits

This article was initially drafted with AI assistance, refined by our editorial team, and finalised following professional review by Distinct Healthcare physicians.

This is original content by Distinct Healthcare, provided for informational purposes only and not intended as medical advice. For personalised guidance, please consult a qualified physician.

Contact: health_content@distincthealth.com

Produced by: Distinct Healthcare · Health Express Team Editorial: Health Express Editorial Team Medical Review: Distinct Healthcare Physician Team